Bladder preservation by combined modality therapy for invasive bladder cancer

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 1022-1029

  Kachnic, L A ^a   Kaufman, D S ^a   Heney, N M ^a   Althausen, A F ^a   Griffin, P P ^a   Zietman, A L ^a   Shipley, W U ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER STAGING; CYSTECTOMY; CYTOLOGY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIMODALITY CANCER THERAPY; ORGAN PRESERVATION; PRIORITY JOURNAL; RELAPSE; SURVIVAL RATE; TRANSURETHRAL RESECTION;

EID: 0031059139     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.1022     Document Type: Article

References (28)

1. Raghavan D, Shipley WU, Garnick MB, et al: Biology and management of bladder cancer. N Engl J Med 322:1129-1138, 1990
2. Thrasher JB, Crawford ED: Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149:957-972, 1993
3. Jenkins BJ, Blandy JP, Caulfield MJ, et al: Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive bladder cancer. Br J Urol 62:343-346, 1988
4. Gospodarowicz MK, Rider WD, Keen CW, et al: Bladder cancer: Long-term follow-up results of patients treated with radical radiation. Clin Oncol 3:155-161, 1991
5. Mameghan H, Fisher R, Mameghan J, et al: Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 31:247-254, 1995
6. Salminen E: External beam radiation treatment of urinary bladder carcinoma. An analysis of results in 203 patients. Acta Oncol 29:909-914, 1990
7. Shipley WU, Rose MA: The selection of patients for treatment by full-dose irradiation. Cancer 55:2278-2284, 1985
8. Schultz TK, Herr HW, Zhang ZF, et al: Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival in patients treated with MVAC with 5-year follow up. J Clin Oncol 12:1394-1401, 1994
9. Scher HI, Geller NE, Curley T, et al: Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol 11:400-407, 1993
10. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncology Group study. J Clin Oncol 3:1463-1470, 1985
11. Skinner DG, Daniels JR, Russell CA, et al: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 145:459-467, 1991
12. Logothetis C, Chong C, Dexeus F, et al: Preliminary results of a prospective randomized trial comparing CISCA to MVAC ehemotherapy for patients (PTS) with advanced transitional cell carcinoma (TCC) of the urothelium. Proc Am Soc Clin Oncol 7:134, 1988 (abstr)
13. Mothersill C, Seymour CB, Cusack A, et al: The effect of radiation and cytotoxic platinum compounds on the growth of normal and tumour bladder explant cultures. Acta Oncol 29:179-184, 1990
14. Soloway MS, Morris CR, Sudderth B: Radiation therapy and cis-diammine-dichloroplatinum (II) in transplantable and primary murine bladder cancer. Int J Radiat Oncol Biol Phys 5:1355-1360, 1979
15. Kaufman DS, Shipley WU, Griffin PP, et al: Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 329:1377-1382, 1993
16. Dunst J, Sauer R, Schrott KM, et al: An organ-sparing treatment of advanced bladder cancer: A 10-year experience. Int J Radiat Oncol Biol Phys 30:261-266, 1994
17. Housset M, Maulard C, Chretien YC, et al: Combined radiation and chemotherapy for invasive transitional-cell cancer of the bladder: A prospective study. J Clin Oncol 11:2150-2157, 1993
18. Tester W, Porter A, Asbell S, et al: Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25:783-790, 1993
19. Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14:119-126, 1996
20. Pollack A, Zagars GN, Swanson DA: Muscle-invasive bladder cancer treated with external beam radiotherapy: Prognostic factors. Int J Radiat Oncol Biol Phys 30:267-277, 1994
21. Given RW, Parsons JT, McCarley D, et al: Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: A five-year follow-up. Urology 46:499-505, 1995
22. Lynch WJ, Jenkins BJ, Fowler CG: The quality of life after radical radiotherapy for bladder cancer. Br J Urol 70:519-521, 1992
23. Kachnic LA, Shipley WU, Griffin PP, et al: Combined modality treatment with selective bladder conservation for invasive bladder cancer: Long-term tolerance in the female patient. Cancer J Sci Am 2:79-84, 1996
24. Logothetis C, Swanson D, Amato R, et al: Optimal delivery of perioperative chemotherapy: Preliminary results of a randomized, prospective comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 155:1241-1245, 1996
25. Sternberg CN, Yagoda A, Scher HI, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 135:461-469, 1988
26. Tannock I, Gospodarowicz M, Connolly J, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 142:289-292, 1989
27. Scher HI: Chemotherapy for invasive bladder cancer: Neoadjuvant vs. adjuvant. Semin Oncol 17:555-565, 1990
28. Sternberg CN, Raghavan D, Ohi Y, et al: Neoadjuvant and adjuvant chemotherapy in advanced bladder cancer - What are the effects on survival and prognosis? Int J Urol 2:76-88, 1995 (suppl)